| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6121365 | Journal of Clinical Virology | 2013 | 7 Pages |
Abstract
The development of coexisting HCMV UL97 and UL54-mutations conferring drug-resistance after HCT is not strictly associated with fatal outcome in one of our three patients. Manifestation of drug resistant combined UL97/UL54-mutations occurred prior to a second VL peak under (V)GCV/PFA co-treatment.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Katharina Göhring, Dana Wolf, Wolfgang Bethge, Elfriede Mikeler, Christoph Faul, Wichard Vogel, Matthias C. Vöhringer, Gerhard Jahn, Klaus Hamprecht,